Dollar General on Thursday reported fiscal fourth-quarter revenue that narrowly beat Wall Street estimates, while a store portfolio review cut into the chain's profit.As part of the reevaluation, the dollar-store chain said it will close 96 Dollar General stores and 45 Popshelf stores and will convert six other Popshelf stores into flagship banner locations in the first quarter. Popshelf stores cater to higher-income shoppers seeking inexpensive products.Shares of the company rose 5% in premarket trading on ...

Dollar General Corporation DG will release its fourth-quarter financial results, before the opening bell, on Thursday, March 13.Analysts expect the Goodlettsville, Tennessee-based company to report quarterly earnings at $1.5 per share, down from $1.83 per share in the year-ago period. Dollar General projects quarterly revenue of $10.26 billion, compared to $9.86 billion a year earlier, according to data from Benzinga Pro.Dollar General has missed analysts’ profit estimates for the last two quarters.Dollar G ...

Casey's General Stores, Inc. (NASDAQ: CASY ) is a convenience store chain that we previously traded and have liked its growth. We have continued to rate the stock a quality and bullish hold, but the valuation hadLooking for opportunistic returns following the big selloff? That is what we are doing at BAD BEAT InvestingEnjoy more rapid-returns with our strategy to advance your savings and retirement timeline by embracing a blended trading and income approach!If you would like, you can try our service out and ...

Shares of the United States' third-largest convenience store and fifth-largest pizza chain, Casey's General Stores (CASY 6.18%), were up 6% as of 11:30 a.m. ET on Wednesday, according to data provided by S&P Global Market Intelligence.Casey's delivered third-quarter earnings that smashed analysts' expectations and showed that its growth prospects remain as bright as ever.Casey's surprisingly good quarter and promising futureFor the third quarter, Casey's reported that earnings before interest, taxes, deprec ...

                                        March 11, 2025 – 5.40 PM CET Regulated information Extraordinary General Meeting of Agfa-Gevaert NV Mortsel, Belgium – March 11, 2025 – 5.40 p.m. CET On Tuesday, March 11, Agfa held an Extraordinary General Meeting at its head office in Mortsel, Belgium. At the meeting, the shareholders approved the reduction of the capital of the Company to the amount of 26,000,000.00 euro by offsetting losses incurred in the amount of 160,794,611.00 euro. Also approved were clarifi ...

Core Viewpoint - Alzamend Neuro is set to initiate a phase II clinical study of AL001 for PTSD treatment in Q4 2025, following the successful completion of a key component for the trial [1][2]. Group 1: Clinical Development - The phase II study will be conducted in collaboration with Massachusetts General Hospital, focusing on AL001's unique properties and its effects on lithium delivery in the brain compared to existing lithium salts [2]. - Previous studies in mice indicated that AL001 allows for better brain absorption of lithium while maintaining lower blood levels, potentially leading to safer treatments [2][5]. Group 2: Treatment Implications - AL001 could eliminate the need for lithium therapeutic drug monitoring (TDM), which has historically complicated the use of lithium in treating bipolar disorder and PTSD [3]. - Current lithium salts have a narrow therapeutic window requiring regular monitoring, which limits their use; however, low doses of lithium carbonate have shown effectiveness in alleviating symptoms in PTSD patients [3][4]. Group 3: Market Potential - The introduction of AL001 could significantly enhance treatment options for over 9 million Americans suffering from PTSD, potentially reshaping treatment paradigms and improving patient quality of life [4]. - AL001 is designed to provide the benefits of marketed lithium salts while reducing associated toxicities, thus addressing the limitations of current lithium therapies [5]. Group 4: Company Overview - Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing treatments for Alzheimer's, bipolar disorder, major depressive disorder, and PTSD [6]. - The company's pipeline includes AL001, a novel lithium-delivery system, and ALZN002, a cell-based therapeutic vaccine aimed at combating Alzheimer's disease [6].

I rate Dollar General (NYSE: DG ) a Buy due to its recession resistant business model and attractive valuation. While the stock has dropped 69%, and the board brought back the old CEO, I think DG will be successful inAnalyst’s Disclosure: I/we have a beneficial long position in the shares of DG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business ...

General Mills (NYSE: GIS ) is not getting much love from investors right now. The stock is trading more than 30% below its all-time high and has significantly underperformed the broader market since the end of 2023.Runner of the TEV Blog | Private InvestorI am a long-term oriented investor and in my early thirties. I hold a law degree and a doctorate in law and love investing and talking about my and others' investments. I regularly write about my research and investments on various investor platforms and t ...

Group 1: Company Performance - General Motors (GM) experienced a strong performance in 2024, with a 9% increase in full-year revenue and leading the U.S. auto market in total, retail, and fleet deliveries [1] - GM doubled its electric vehicle (EV) market share in 2024, and its EV portfolio became variable profit positive in the fourth quarter [1] - The company reported positive equity income for the fourth quarter in China, despite challenges in a competitive market [6] Group 2: Shareholder Value - GM announced a 25% increase in its dividend, raising it by $0.03 per share, and authorized a new $6 billion share repurchase program [3] - The company has repurchased approximately $22 billion in shares since the end of 2023, contributing to a 48% gain in its stock price during 2024 [6] - GM's stock is trading at a modest price-to-earnings ratio of 7.4, indicating potential value for investors [5][7] Group 3: Strategic Execution - GM's capital allocation strategy focuses on reinvesting in profitable growth, maintaining a strong investment-grade balance sheet, and returning capital to shareholders [4] - The company remains confident in its ability to navigate potential challenges, such as tariffs on Canadian and Mexican imports, which reassures investors [7] - GM continues to improve the profitability of its EV lineup, suggesting further upside potential [8]

撰文 / 钱亚光 设计 / 师 超 2025年，美国电动汽车行业即将迎来一个重要里程碑，那就是将有超10家新的电池工厂投产。 据基准矿产情报公司（Benchmark Mineral Intelligence）的数据，这些设施得到了像 LGES、SK On、三星这样的行业巨头以及丰田、福特、本田、现 代、特斯拉和Stellantis等汽车制造商的支持，它们将使美国的电池制造能力增长至 421.5 GWh，几乎是之前的两倍。 据考克斯汽车公司《凯利蓝皮书（Kelly Blue Book）》的统计，2024年全年，电动汽车销量超过130万辆，同比增长了7.3%，而汽车市场整体同比增长 只有2%多一点。 2024年，电动汽车占据了8.1%的市场份额；2023年，美国所有新车销量的7.3%是全电动的；2022年，美国人购买的新车中有5.8%是全电动的，高于 2021年的3.2%。 通用、福特、现代等几家汽车制造商在过去两年中报告称，电动汽车销量强劲增长，在很大程度上得益于消费者激励措施和有利的融资。随着更多电池 产能即将在美国本土建成，人们对于减少美国对国外关键电动汽车零部件的依赖寄予了厚望。 其次，降低成本。随着电池 ...